Lin JX, Zhou Q, Yan HH, Liu AW, et al. A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203). Clin Lung Cancer 2025 May 28:S1525-7304(25)00127.
PMID: 40541556